» Articles » PMID: 37497381

Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is considerable variation in reported chronic obstructive pulmonary disease (COPD) prevalence internationally, partly due to differing definitions in use. Accurate estimates of disease prevalence are important for allocation of health-care resources, yet UK estimates of COPD prevalence have not been updated for a decade. We calculated yearly COPD prevalence in England between 2000 and 2019 using different definitions of COPD.

Methods: We used routinely collected primary care electronic healthcare record (EHR) data from the Clinical Practice Research Datalink (CPRD) Aurum database linked with secondary care data from the Hospital Episode Statistics (HES) Admitted Patient Care (APC) database. Mid-year point prevalence was calculated yearly from 2000 to 2019 in English adults aged ≥40 years using 5 definitions: (i) validated COPD, (ii) Quality and Outcomes Framework (QOF) COPD, (iii) COPD symptoms, inhaler prescription, and no asthma diagnosis, (iv) hospitalisation with COPD as any diagnosis, (v) hospitalisation with COPD as primary or secondary diagnosis. Prevalence was further stratified by gender, age group, and region.

Results: A total of 12,745,793 people were included over the 20-year period. Annual cohort sizes ranged from 4,373,538 in 2000 to 6,159,496 in 2019. Estimates of COPD prevalence increased every year from 2000 and the difference in estimated prevalence between the validated and QOF definitions has grown over time. In 2019, a COPD prevalence of 4.9% was found using validated events in either primary or secondary care (definition 1 or definition 5). Additionally, including potentially undiagnosed cases (definition 3) in the COPD definition produced an increased prevalence of 6.7%.

Conclusion: Common definitions of COPD (eg, QOF codes), may underestimate the true prevalence. The extent of this underestimate has increased over time and could lead to under-allocation of resources where need is estimated based on these definitions. Standardisation of COPD coding in routine EHRs and metrics such as spirometry is key to accurate disease monitoring.

Citing Articles

Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study.

Corby G, Barclay N, Tan E, Burn E, Delmestri A, Duarte-Salles T Transl Lung Cancer Res. 2024; 13(9):2187-2201.

PMID: 39430337 PMC: 11484731. DOI: 10.21037/tlcr-24-241.


Vitamin D for the management of chronic obstructive pulmonary disease.

Williamson A, Martineau A, Jolliffe D, Sheikh A, Janssens W, Sluyter J Cochrane Database Syst Rev. 2024; 9:CD013284.

PMID: 39329240 PMC: 11428191. DOI: 10.1002/14651858.CD013284.pub2.


Patient pathways for four major chronic respiratory diseases in England between 2008 and 2021.

Ioannides A, Morgan A, Quint J BMJ Open Respir Res. 2024; 11(1).

PMID: 39209353 PMC: 11367335. DOI: 10.1136/bmjresp-2023-002273.


UK Electronic Healthcare Records for Research: A Scientometric Analysis of Respiratory, Cardiovascular, and COVID-19 Publications.

Massen G, Blamires O, Grainger M, Matta M, Twumasi R, Joshi T Pragmat Obs Res. 2024; 15:151-164.

PMID: 39161588 PMC: 11332414. DOI: 10.2147/POR.S469973.


A Harmonised Approach to Curating Research-Ready Datasets for Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Interstitial Lung Disease (ILD) in England, Wales and Scotland Using Clinical Practice Research Datalink (CPRD), Secure Anonymised....

Hatam S, Scully S, Cook S, Evans H, Hume A, Kallis C Clin Epidemiol. 2024; 16:235-247.

PMID: 38595770 PMC: 11002787. DOI: 10.2147/CLEP.S437937.


References
1.
Davidson J, Banerjee A, Mathur R, Ramsay M, Smeeth L, Walker J . Ethnic differences in the incidence of clinically diagnosed influenza: an England population-based cohort study 2008-2018. Wellcome Open Res. 2021; 6:49. PMC: 8136253. DOI: 10.12688/wellcomeopenres.16620.3. View

2.
Halpin D, Miravitlles M . Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006; 3(7):619-23. DOI: 10.1513/pats.200603-093SS. View

3.
Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J . Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest. 2003; 123(6):1916-23. DOI: 10.1378/chest.123.6.1916. View

4.
Ladwig K, Marten-Mittag B, Formanek B, Dammann G . Gender differences of symptom reporting and medical health care utilization in the German population. Eur J Epidemiol. 2000; 16(6):511-8. DOI: 10.1023/a:1007629920752. View

5.
Kinnula V, Vasankari T, Kontula E, Sovijarvi A, Saynajakangas O, Pietinalho A . The 10-year COPD Programme in Finland: effects on quality of diagnosis, smoking, prevalence, hospital admissions and mortality. Prim Care Respir J. 2011; 20(2):178-83. PMC: 6549818. DOI: 10.4104/pcrj.2011.00024. View